局部胰腺癌完整病灶调强质子治疗的初步经验:临床实施、剂量学分析、急性治疗相关不良事件及患者报告结局
本研究在2016年7月至2017年3月纳入13例局部胰腺癌患者,采用笔束扫描调强质子治疗(IMPT)联合卡培他滨或5-氟尿嘧啶为基础放化疗,剂量50 Gy(相对生物效应1.1),并与容积旋转调强放疗(VMAT)进行配对剂量学比较。IMPT靶区覆盖与VMAT无差异,但显著降低小肠、十二指肠、胃、大肠、肝脏和肾脏剂量;无≥3级治疗相关不良事件,患者报告结局无显著变化。作者认为IMPT可行,但结论受样本量限制,需进一步临床研究验证剂量学优势能否转化为临床获益。
要点
- IMPT靶区覆盖与VMAT无差异(P > .05),但显著降低多个危及器官剂量(P < .05)。
- 所有患者完成治疗无放疗中断,中位体重下降1.6 kg(范围0.1-5.7 kg),无≥3级治疗相关不良事件。
- FACT-Hep评分放疗前中位142(范围113-163) vs 放疗结束时136(范围107-173),P = .18,无显著变化。
核心结论
- 笔束扫描IMPT可行,并显著降低多个胃肠道危及器官的辐射暴露。
- IMPT与无≥3级胃肠道不良事件及基线患者报告结局无变化相关,但结论受患者样本量限制。
- 需要进一步临床研究评估这些剂量学优势能否转化为有临床意义的获益。
研究设计与样本
- 2016年7月至2017年3月纳入13例局部胰腺癌患者,接受IMPT同步卡培他滨或5-氟尿嘧啶为基础放化疗,剂量50 Gy(相对生物效应1.1)。
- 为每例患者生成VMAT计划用于配对剂量学比较。
- 前瞻性评估急性不良事件,并在基线和放化疗结束时采用癌症治疗功能评估-肝胆量表完成患者报告结局问卷。
主要发现
- IMPT与VMAT的平均靶区覆盖无差异(P > .05)。
- IMPT显著降低小肠、十二指肠、胃、大肠、肝脏和肾脏的剂量(P < .05)。
- 所有患者完成治疗无放疗中断,治疗期间中位体重下降1.6 kg(范围0.1-5.7 kg)。
- 无患者发生≥3级治疗相关不良事件。
- 放化疗前 vs 放化疗结束时中位FACT-Hep评分分别为142(范围113-163) vs 136(范围107-173),P = .18。
局限性
- 结论受患者样本量限制。
- 需要进一步临床研究评估剂量学优势能否转化为有临床意义的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pencil-beam scanning intensity modulated proton therapy (IMPT) may allow for an improvement in the therapeutic ratio compared with conventional techniques of radiation therapy delivery for pancreatic cancer. The purpose of this study was to describe the clinical implementation of IMPT for intact and clinically localized pancreatic cancer, perform a matched dosimetric comparison with volumetric modulated arc therapy (VMAT), and report acute adverse event (AE) rates and patient-reported outcomes (PROs) of health-related quality of life. METHODS AND MATERIALS: Between July 2016 and March 2017, 13 patients with localized pancreatic cancer underwent concurrent capecitabine or 5-fluorouracil-based chemoradiation therapy (CRT) utilizing IMPT to a dose of 50 Gy (radiobiological effectiveness: 1.1). A VMAT plan was generated for each patient to use for dosimetric comparison. Patients were assessed prospectively for AEs and completed PRO questionnaires utilizing the Functional Assessment of Cancer Therapy-Hepatobiliary at baseline and upon completion of CRT. RESULTS: There was no difference in mean target coverage between IMPT and VMAT (P > .05). IMPT offered significant reductions in dose to organs at risk, including the small bowel, duodenum, stomach, large bowel, liver, and kidneys (P < .05). All patients completed treatment without radiation therapy breaks. The median weight loss during treatment was 1.6 kg (range, 0.1-5.7 kg). No patients experienced grade ≥3 treatment-related AEs. The median Functional Assessment of Cancer Therapy-Hepatobiliary scores prior to versus at the end of CRT were 142 (range, 113-163) versus 136 (range, 107-173; P = .18). CONCLUSIONS: Pencil-beam scanning IMPT was feasible and offered significant reductions in radiation exposure to multiple gastrointestinal organs at risk. IMPT was associated with no grade ≥3 gastrointestinal AEs and no change in baseline PROs, but the conclusions are limited due to the patient sample size. Further clinical studies are warranted to evaluate whether these dosimetric advantages translate into clinically meaningful benefits.
引用
- Jethwa KR, Tryggestad EJ, Whitaker TJ, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol. 2018. PMID: 30202800. doi:10.1016/j.adro.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。